Lee Greenberger

Dec 10, 2024 | healio.com | Josh Friedman |Mindy Valcarcel |Lee Greenberger

You've successfully added Lymphoma to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:HSCT did not benefit patients with mantle cell lymphoma in complete remission with undetectable minimal residual disease. Transplantation may help those with minimal residual disease after induction.

Jun 27, 2024 | lls.org | Lee Greenberger

Immunotherapy uses the power of the immune system to treat blood cancer. Today it is a standard treatment that has a profound effect in some blood cancer patients, but it still falls short in others. The Leukemia & Lymphoma Society (LLS) has been a champion of this type of cancer treatment for decades, supporting some of the earliest and most game-changing immune-based treatments for blood cancer. The advances have been astonishing, but there is so much further to go.

Jan 22, 2024 | cancerhealth.com | Lee Greenberger

By Lee Greenberger, PhD, LLS Chief Scientific Officer More than 25,000 medical professionals from across the world came together in December to discuss the latest blood cancer developments during the annual meeting of the American Society of Hematology (ASH). This annual event gives us the opportunity to think about what advances are on the horizon as LLS works to strengthen cures, care and quality of life for people with blood cancer and their families.

Jan 17, 2024 | lls.org | Lee Greenberger

More than 25,000 medical professionals from across the world came together in December to discuss the latest blood cancer developments during the annual meeting of the American Society of Hematology (ASH). This annual event gives us the opportunity to think about what advances are on the horizon as LLS works to strengthen cures, care and quality of life for people with blood cancer and their families.

Dec 11, 2023 | healio.com | Matthew Shinkle |Drew Amorosi |Lee Greenberger |Naveen Pemmaraju

You've successfully added Hematology Oncology: Myeloproliferative Neoplasms to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Navitoclax plus ruxolitinib led to improvement in spleen volume reduction in patients with untreated myelofibrosis.